These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 29634960)

  • 1. A PDE multiscale model of hepatitis C virus infection can be transformed to a system of ODEs.
    Kitagawa K; Nakaoka S; Asai Y; Watashi K; Iwami S
    J Theor Biol; 2018 Jul; 448():80-85. PubMed ID: 29634960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mathematical Analysis of a Transformed ODE from a PDE Multiscale Model of Hepatitis C Virus Infection.
    Kitagawa K; Kuniya T; Nakaoka S; Asai Y; Watashi K; Iwami S
    Bull Math Biol; 2019 May; 81(5):1427-1441. PubMed ID: 30644067
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Searching for synergy: Identifying optimal antiviral combination therapy using Hepatitis C virus (HCV) agents in a replicon system.
    Pomeroy JJ; Drusano GL; Rodriquez JL; Brown AN
    Antiviral Res; 2017 Oct; 146():149-152. PubMed ID: 28882564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mathematical analysis of multiscale models for hepatitis C virus dynamics under therapy with direct-acting antiviral agents.
    Rong L; Perelson AS
    Math Biosci; 2013 Sep; 245(1):22-30. PubMed ID: 23684949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model.
    Rong L; Guedj J; Dahari H; Coffield DJ; Levi M; Smith P; Perelson AS
    PLoS Comput Biol; 2013; 9(3):e1002959. PubMed ID: 23516348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in "special populations".
    Pol S; Parlati L
    Liver Int; 2018 Feb; 38 Suppl 1():28-33. PubMed ID: 29427485
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamical Analysis of a Multiscale Model of Hepatitis C Virus Infection Using a Transformed ODEs Model.
    Elkaranshawy HA; Ezzat HM; Ibrahim NN
    Annu Int Conf IEEE Eng Med Biol Soc; 2020 Jul; 2020():2451-2454. PubMed ID: 33018502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals.
    Rockstroh JK
    Liver Int; 2015 Jan; 35 Suppl 1():51-5. PubMed ID: 25529087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Parameter Estimation Method for Multiscale Models of Hepatitis C Virus Dynamics.
    Reinharz V; Churkin A; Lewkiewicz S; Dahari H; Barash D
    Bull Math Biol; 2019 Oct; 81(10):3675-3721. PubMed ID: 31338739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Therapies for Hepatitis C Virus.
    Polenakovik H
    Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the treatment of hepatitis B virus/hepatitis C virus coinfection.
    Sagnelli E; Pisaturo M; Martini S; Sagnelli C; Filippini P; Coppola N
    Expert Opin Pharmacother; 2014 Jul; 15(10):1337-49. PubMed ID: 24773464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiviral resistance and direct-acting antiviral agents for HCV.
    Aloia AL; Locarnini S; Beard MR
    Antivir Ther; 2012; 17(6 Pt B):1147-62. PubMed ID: 23188771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future hepatitis C virus treatment: interferon-sparing combinations.
    Gane E
    Liver Int; 2011 Jan; 31 Suppl 1():62-7. PubMed ID: 21205140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection.
    Spengler U
    Pharmacol Ther; 2018 Mar; 183():118-126. PubMed ID: 29024739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
    Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
    Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The era of direct-acting antivirals has begun: the beginning of the end for HCV?
    Vachon ML; Dieterich DT
    Semin Liver Dis; 2011 Nov; 31(4):399-409. PubMed ID: 22189979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Progress in Examination and Treatment of Hepatitis C Virus].
    Suda G; Sakamoto N
    Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.
    Lin M; Kramer J; White D; Cao Y; Tavakoli-Tabasi S; Madu S; Smith D; Asch SM; El-Serag HB; Kanwal F
    Aliment Pharmacol Ther; 2017 Nov; 46(10):992-1000. PubMed ID: 28949020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of drug interactions with direct-acting antivirals in Dutch HIV/hepatitis C virus-coinfected patients: adequate but not perfect.
    Smolders EJ; Smit C; de Kanter C; Dofferhoff A; Arends JE; Brinkman K; Rijnders B; van der Valk M; Reiss P; Burger DM;
    HIV Med; 2018 Mar; 19(3):216-226. PubMed ID: 29194939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.